As consumers are clamoring for access to pricey GLP-1 drugs for weight loss, employers are feeling the need to modify or update their plans to accommodate new demands and costs.
KFF’s 2024 Employer Health Benefits Survey analyzed responses from 2,142 interviews with non-federal public and private firms to determine if employers are covering GLP-1s.
